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ABSTRAK
Latar belakang: ekspresi dari CD30, CD15, CD50, dan PAX5, digunakan untuk membantu mengkonfirmasi 
diagnosis HL dan sALCL; namun belum ada data mengenai proporsi ekspresi dari penanda-penanda ini. 
Penelitian ini bertujuan mengetahui proporsi ekspresi positif dari CD30, CD15, CD50, dan PAX5 serta 
karakteristik pasien HL dan sALCL di RS Pusat Kanker Dharmais pada periode tahun 2005-2015. Metode: studi 
retrospektif observasional ini dilakukan dengan menggunakan data rekam medis dan hasil patologi pada pasien 
dewasa HL dan sALCL yang mendapatkan terapi di rumah sakit antara tahun 2005 dan 2015. Pemeriksaan 
imunohistokimia dilakukan dan data proporsi ekspresi positif dari CD30, CD15, CD50, dan PAX5 dianalisis 
secara deskriptif. Hasil: sebanyak 45 pasien direkrut dalam studi ini dengan mayoritas (42 pasien, 93,3%) 
adalah pasien HL dan hanya 3 (6,7%) yang merupakan pasien sALCL. Nilai median usia pasien HL lebih 
rendah dibandingkan pasien sALCL, yaitu 35 (18-72) tahun versus 54 (49-61) tahun. Dari hasil pemeriksaan 
imunohistokimia pada pasien HL, ditemukan ekspresi positif dari CD15, CD30, CD50, PAX5 berturut-turut 
sebesar 37,5%; 88,9%; 31,2%; dan 31,2%. Dengan keterbatasan jumlah pasien sALCL, ditemukan ekspresi 
positif dari CD30, CD15, CD50, dan PAX5 berturut-turut sebesar 100%; 66,7%; 50%; dan 50%. Pada 
keseluruhan pasien HL dan sALCL proporsi ekspresi positif dari CD15, CD50, dan PAX5 sebesar 39.5%, 
32.4%, dan 32.4%, sedangkan ekspresi positif dari CD30 sebesar 89.5%. Kesimpulan: studi ini menunjukkan 
bahwa hampir 90% pasien memberikan ekspresi positif CD30, sedangkan  yang mengekspresikan positif CD15, 
CD50, dan PAX5 terdapat pada kurang dari 40% pasien. Hasil studi ini mengindikasikan bahwa pemeriksaan 
CD30 merupakan penanda diagnosis yang penting untuk HL dan sALCL dan mungkin dapat digunakan untuk 
memperbaiki strategi pengobatan.
Kata kunci: ekspresi C30, CD15, CD50, PAX5, limfoma hodgkin, systemic anaplastic large cell lymphoma 
(sALCL), limfoma, imunohistokimia.
ABSTRACT
Background: the expression of CD30, CD15, CD50, and PAX5 are used to help in confirming diagnosis of 
HL and sALCL; however data on the proportion of these markers have not been available. The study was aimed 
to identify the proportion of CD30, CD15, CD50 and PAX5 expressions and characteristics of patients with HL 
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and sALCL at Dharmais National Cancer Center Hospital between 2005 and 2015. Methods: a retrospective 
observational study was conducted using data from medical records and histopathological results of HL and 
sALCL adult patients who sought treatment at the hospital between 2005 and 2015. Immunohistochemistry 
(IHC) examinations were performed and data on the proportion of positive CD30, CD15, CD50, and PAX5 
expressions were analyzed descriptively. Results: a total of 45 patients were recruited in this study, with the 
majority (42 patients, 93.3%) were HL patients and only 6.7% were sALCL patients. The median age of HL 
patients was younger than sALCL patients; 35 (18-72 years old) versus 54 (49-61 years old). Moreover, the 
immunohistochemistry examination demonstrated that the positive CD15, CD30, CD50, and PAX5 expressions 
were found respectively in 37.5%, 88.9%, 31.2%, and 31.2% patients with HL; while in patients with sALCL, 
in spite of their small sample size, positive CD30, CD15, CD50 and PAX5 expressions were found in 100%; 
66,7%; 50%; and 50%, respectively. Overall, CD15, CD50, and PAX5 positive expressions were found in 39.5%, 
32.4%, and 32.4% patients who had HL and sALCL; while positive expression of CD30 was found in 89.5% 
of them. Conclusion: present study shows that almost 90% patients have positive CD30 expression;  while the 
positive expressions of CD15, CD50, and PAX5 are found in less than 40% patients. It indicates that CD30 is 
an important diagnostic marker for HL and sALCL and it may improve treatment strategy.
Keywords: CD30, CD15, CD50, PAX5 expression, hodgkin lymphoma, systemic anaplastic large cell 
lymphoma (sALCL), lymphoma, immunohistochemistry.
INTRODUCTION
The incidence of Hodgkin Lymphoma 
(HL) in Asian countries is relatively lower 
than Western countries. The annual incidence 
rate in the US and the UK is 2.8 and 2.4 
per 100,000 population, respectively. These 
numbers are particularly higher than most 
Asian countries.1-3 The 5-year survival rate has 
improved from less than 10% in the 1960s to 
over 80% in 2012. It is considered one of the 
most curable cancers.4,5 The improved survival 
rate might be due to improved physicians’ skill 
in classifying disease and determining the most 
effective treatment based on different pattern of 
gene expression including providing targeted 
therapy or monoclonal antibody.6 Despite the 
high success rate of the initial treatment with 
chemotherapy and radiotherapy for HL and 
sALCL, the relapse rate is 20-30%.7
Approximately 9% of lymphoma patients or 
about 10 patients per year at Dharmais Hospital 
National Cancer Center are diagnosed with 
Hodgkin Diseases based on our unpublished 
internal report. Unfortunately, 41% of all subjects 
are classified as HL not otherwise specified 
(NOS), due to financial inability to conduct 
immunohistochemistry (IHC) testing for all 
subjects.8
IHC is an essential part of diagnostic tools 
for lymphoma malignancies; however, it has not 
been considered a routine test in daily practice. 
Various types of lymphoma have different and 
specific expressions of IHC markers. WHO 
classifies HL based on the immunophenotype 
of Reed-Stemberg (RS) cells into two subtypes: 
nodular lymphocyte predominant HL (NLPHL) 
with immunohistochemical characteristics 
of CD45RB+, CD20+, Epithelial Membrane 
Antigen (EMA)+/-, EBER- and Classical HL 
(CHL) with CD45RB-, CD30+, CD15+, EBV-
encoded RNA(EBER)+/-.9 The gene experession 
of CD30+ has been reported in almost patients 
with CHL, while the experession of CD15+ has 
been found in 59-93% of CHL cases.10,11
Results from IHC in patients with HL and 
sALCL can help in diagnosis as well as treatment 
decision. Antibody-based immunotherapy has 
emerged as the novel treatment for patients with 
HL and sALCL. These new therapies could target 
malignant cells which express certain antibody. 
For instance, brentuximab vedotin is an anti-
CD30 antibody-drug conjugate (ADC), while 
CD30 is an important therapeutic target for the 
treatment of patients with HL and sALCL who 
have positive CD30 expression.
Currently, little is known about the IHC 
profile of lymphoma patients in Indonesia; while 
the use of IHC testing has become increasingly 
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significant for the prognosis and treatment. The 
expressions of CD30, CD15, CD50 and PAX5 
are used to provide help in establishing diagnosis 
of HL and sALCL. CD30 is highly expressed in 
patients with HL and sALCL.12,13 Furthermore, 
CD30 may also contribute to prognosis and 
treatment decision.14,15 The aim of our study 
was to identify the proportion of positive CD30, 
CD15, CD50, and PAX5 expressions and 
characteristics of patients with HL and sALCL 
at Dharmais Hospital, National Cancer Center 
between 2005 and 2015.
METHODS
The study was a retrospective observational 
study using secondary data from Dharmais 
National Cancer Center Hospital between 
January 2005 and October 2015. Data were 
obtained from medical records and results of IHC 
analyses, which were performed using paraffin 
blocks with specimens obtained from patients 
with HL and/or sALCL. 
The IHC testing was performed based on 
routine standard operational procedure at the 
hospital using labeled Streptavidin-Biotin 
(LSAB) staining method. Paraffin blocks of the 
study sample were cut into 4 micron pieces and 
then attached to a SuperfrossPluss (Ventana) 
glass object, and then heated over a warmer slide 
at 60°C for 30 minutes.
The evaluation of CD30, CD15, CD50 and 
PAX5 expressions were carried out using the 
Benchmark XT, an automated IHC slide staining 
instrument, according to the standard IHC 
protocol. All data were evaluated descriptively 
and were presented in narrative texts and tables.
Ethical Approval
The study was conducted in compliance with 
the Good Clinical Practice (GCP) principle as has 
been defined by the International Conference on 
Harmonization (ICH) and was also performed in 
accordance with the Indonesian National Agency 
for Drug and Food Control Guideline. Ethical 
approval was obtained from the Health Research 
Ethics Committee, Dharmais National Cancer 
Center Hospital on December 15th, 2015, with 
a reference number: KEPK/046/XII/2015.
RESULTS
As many as 42 HL patients and 3 sALCL 
patients were enrolled in the study. In general, 
patients who were diagnosed with HL were 
younger than those with sALCL (median age: 
35 vs. 54 years) as can be seen in Table 1. Based 
on tumor staging, 12 out of 22 (54.5%) HL 
patients were found in advanced stage (stage 3 
and 4). There were limited clinical data about out 
study subjects. In the group with HL, we found 
four patients who had relapsed after receiving 
initial treatment and five patients with partial 
responses. Moreover, regarding the laboratory 
results, one patients in the sALCL group had a 
high erythrocyte sediment rate (ESR) [Table 2].
Table 1. Subject characteristics
Characteristics HL (n=42) sALCL (n=3)
Age, Median (Min-Max) 35 (18-72) 54 (49-61)
Sex, n (%)
 - Male 20 (47.6) 3 (100.0)
 - Female 22 (52.4) 0 (0.0)
Weight (Kg), Median 
(Min-Max) 54.5 (37-100) 62.5 (57-68)
Height (cm), Median 
(Min-Max) 161 (142-180) 166 (164-168)
ECOG Performance status
 - 0 0 (0.0) 1 (100.0)
 - 1 4 (100.0) 0 (0.0)
B-symptoms
 - Yes 13 (76.5) 0 (0.0)
 - No 4 (23.5) 1 (100.0)
Comorbidities
 - Yes 13 (40.6) 0 (0.0)
 - No 19 (59.4) 3 (100.0)
Stage of disease
 - 1 1 (4.2) 0 (0.0)
 - 2 9 (37.4) 1 (100.0)
 - 3 6 (25.0) 0 (0.0)
 - 4 6 (25.0) 0 (0.0)
Progressive 1 (4.2) 0 (0.0)
Refracter 1 (4.2) 0 (0.0)
Bulky tumor
 - Yes 8 (29.6) 0 (0.0)
 - No 19 (70.4) 1 (100.0) 
Extranodal
 - Yes 7 (28.0) 0 (0.0)
 - No 18 (72.0) 1 (100.0)
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Histopathology and Expressions of CD30, 
CD15, CD50, and PAX5
Histopathological data was obtained from 
34 out of 42 HL patients. In Table 3, we can see 
that most HL subjects have histopathology types 
of mixed cellularity (10 out of 34) and nodular 
sclerosis (9 out of 34). We also assessed the IHC 
markers of the subjects. In HL patients, CD30 
were positively expressed in almost all patients 
(32 out of 36), while CD15, CD50 and PAX5 
were positively expressed in 37.5%, 31.2%, 
and 31.2% patients respectively. Despite the 
small sample size of of sALCL patients, positive 
expressions of CD30 and CD15 were found in 
100% and 66.7% subjects, respectively. [Table 
4].
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 - Positive 1 (6.2) 0 (0.0)
 - Negative 15 (93.8) 1 (100.0)
AntiHCV, n (%)
 - Reactive 0 (0.00) 0 (0.0)
 - Non-
reactive 14 (100.00) 1 (100.0)
Table 3. Histopathological subtypes of HL patients (n=42)
Histopathological subtypes n (%)
Mixed cellularity 10 (23.8)
Nodular sclerosis 9 (21.4)
Lymphocyte predominance 8 (19.1)
Lymphocyte depletion 4 (9.5)
Lymphocyte rich 3 (7.1)
Not available 8 (19.1)
Table 4. IHC marker expressions of the study subjects
Variables HL sALCL HL + sALCL
CD15, n (%)
 - Positive 15 (37.5) 2 (66.7) 17 (39.5)
 - Negative 25 (62.5) 1 (33.3) 26 (60.5)
CD30, n (%)
 - Positive 32 (88.9) 2 (100.0) 34 (89.5)
 - Negative 4 (11.1) 0 (0.0) 4 (10.5)
CD50, n (%)
 - Positive 10 (31.2) 1 (50.0) 11 (32.4)
 - Negative 22 (68.8) 1 (50.0) 23 (67.6)
Pax 50, n (%)
 - Positive 10 (31.2) 1 (50.0) 11 (32.4)
 - Negative 22 (68.8) 1 (50.0) 23 (67.6)
DISCUSSION
In our study, we reported the proportion of 
patients with positive CD30, CD15, CD50, and 
PAX5 gene expression within a 10-year period. 
The analysis was conducted retrospectively 
on paraffin blocks of HL and sALCL patients 
who previously may or may not have IHC 
examination. We observed that less than 40% 
of the patients had positive CD15, CD50 and 
PAX5 gene expressions; while almost 90% of 
the patients had positive CD30 expression.
More than 80% of our patients had common 
type HL histopathological subtypes,16 i.e. mixed 
cellularity and nodular sclerosis. The age 
distribution in our HL population (median age 
of 35 years old) was similar to HL population in 
Korea (median age of 39 years old);17 however, 
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our patients were much older than patients in 
Taiwan (median age of 26 years old).18 Our study 
has also demonstrated typical features of HL and 
sALCL cases with rare B symptoms, extra nodal 
involvement and bulky tumor.
Data about treatment outcomes using first-
line treatment, i.e. conventional chemotherapy 
and radiotherapy were only obtained from HL 
patients. After first-line treatment, our follow-up 
data showed that 5 out of 9 patients had partial 
response, while others had progressive course 
of illness. Four HL patients had relapses after 
having first remission. Wu et al18 in Taiwan 
observed a cumulative relapse rate of 23% at 10 
years among their 115 HL patients.
HL and sALCL are difficult to diagnose. 
Confirmed diagnosis is important since 80% 
cases of sALCL can be cured with modern 
regimens of chemotherapy and radiotherapy.19,20 
HL diagnosis is usually confirmed by IHC 
examination. The findings of positive CD15 
gene expression can be an indicator for the 
presence of sALCL.16,21 However, in our study, 
12 HL patients who were found with positive 
CD30 expression also showed positive CD15 
expression, whereas only one sALCL patient 
had positive expression of both CD15 and CD30 
since there was only a small sample size for 
this group. Further studies with larger size are 
recommended in order to confirm these findings.
In addition to positive CD15 expression, 9 
out of 29 HL patients also had positive PAX5 
expression; while 1 sALCL patient also had 
positive PAX5 expression. PAX5 is a B-cell-
specific activator protein, which has a major 
role in B-cell differentiation and can be used 
to confirm the diagnosis.22 It indicates that IHC 
examination alone is not sufficient as a diagnostic 
tool. Further phenotypic testing is necessary to 
confirm the diagnosis. CD30, which is a cell 
surface receptor, has been identified in 1982 as 
an important therapeutic target for treatment of 
lymphomas. Several monoclonal antibodies that 
bind CD30 (and another receptor) may attract 
immune cells that generate anti-tumor response.21 
Due to a high response rate of HL and sALCL 
patients with positive CD30 expression to some 
targeted therapy, the CD30 testing is considered 
as an important tool to determine the therapeutic 
options.21,23
There are some limitations in our study 
including the absence link between paraffin block 
and medical record data, which might affect the 
number of recruited subject. Nevertheless, our 
study is the first study in our center, as well as 
the first in Indonesia, which demonstrate the 
profile of CD30, CD15, CD50 and PAX5 in 
patients with HL and sALCL. It is expected that 
our study can provide the basic information on 
clinical, histological and immunohistochemical 
characteristics of patients with lymphoma in 
Indonesia.
CONCLUSION
89.5% of the patients have positive CD30 
expression, while the proportion of patient with 
positive CD15, CD50 and PAX5 gene expression 
are less than 40%. Since HL and sALCL are not 
commonly found in Asia, we hope that our study 
could provide essential information about HL 
and sALCL patients in Asia, which eventually 
can provide information for better therapeutic 
options.
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